sentence: In a phase II clinical trial NCT02643550 for the treatment of SCCHN , monalizumab combined with cetuximab , an anti-EGFR monoclonal antibody , resulted in a partial response rate of 31 % , and stable disease at 54 % , compared with the historical data of 13 % objective response rate for single agent cetuximab , showing that NKG2A blockade has the potential of treating tumor patients in combination with tumor-targeting antibodies .